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We hypothesized that bone marrow-derived mononuclear cells (BMDMC) would attenuate the remod-
eling process in a chronic allergic inﬂammation model. C57BL/6 mice were assigned to two groups.
In OVA, mice were sensitized and repeatedly challenged with ovalbumin. Control mice (C) received
saline under the same protocol. C and OVA were further randomized to receive BMDMC (2×106) or
saline intravenously 24h before the ﬁrst challenge. BMDMC therapy reduced eosinophil inﬁltration,
smooth muscle-speciﬁc actin expression, subepithelial ﬁbrosis, and myocyte hypertrophy and hyper-tem cells
sthma
plasia, thus causing a decrease in airway hyperresponsiveness and lung mechanical parameters. BMDMC
fromgreen ﬂuorescent protein (GFP)-transgenicmice transplanted into GFP-negativemice yielded lower
engraftment in OVA. BMDMC increased insulin-like growth factor expression, but reduced interleukin-5,
transforming growth factor-, platelet-derived growth factor, and vascular endothelial growth factor
mRNA expression. In conclusion, in the present chronic allergic inﬂammation model, BMDMC therapy
tmen
elingwas an effective pre-trea
inﬂammatory and remod
. Introduction
Recently, new attention has been directed to the long-term
hanges in asthmatic airways as indicated by the accelerated rate
f lung function decline despite therapy with inhaled corticos-
eroids. These structural changes in the airwaywall, termed airway
emodeling, are now thought to be a key component of the patho-
hysiology of asthma. Airway remodeling is characterized by:
ubepithelial ﬁbrosis, mucous metaplasia, wall thickening, smooth
uscle cell hypertrophy and hyperplasia, myoﬁbroblast hyperpla-
ia, vascular proliferation, and changes in the extracellular matrix,
uch as deposition of collagen ﬁber and elastic ﬁber fragmenta-
ion (Holgate et al., 2004; Xisto et al., 2005). Therefore, a therapy
hat hastens the repair process and attenuates both inﬂammatory
nd remodeling responses is thought to be important to improve
sthma management.
∗ Corresponding author at: Laboratory of Pulmonary Investigation, Carlos Chagas
ilho Biophysics Institute, Federal University of Rio de Janeiro, Centro de Ciências
a Saúde, Avenida Carlos Chagas Filho, s/n, Bloco G-014, Ilha do Fundão, 21941-902,
io de Janeiro, RJ, Brazil. Tel.: +55 21 2562 6530; fax: +55 21 2280 8193.
E-mail addresses: prmrocco@biof.ufrj.br, prmrocco@gmail.com (P.R.M. Rocco).
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Open access under the Elsevier OA license.t protocol that potentiated airway epithelial cell repair and prevented
processes.
© 2010 Elsevier B.V. 
Bone marrow-derived stem cells are potent modulators
of immune responses, promoting the proliferation and re-
epithelization of lung cells. Several studies have shown beneﬁcial
effects of cell-based therapy in respiratory diseases (Rojas et al.,
2005; Gupta et al., 2007; Zhao et al., 2008; Zhen et al., 2008) result-
ing from cell plasticity (Krause, 2002; Herzog et al., 2003) and/or
the release of paracrine factors (Rojas et al., 2005; Ortiz et al., 2007).
So far, however, no study has analyzed the effects of bone marrow-
derived stem cells in experimental allergic asthma.
We tested the hypothesis that pre-treatment with bone
marrow-derivedmononuclear cells (BMDMC)may prevent inﬂam-
matory and remodeling processeswhile improving lung function in
a murine model of chronic allergic inﬂammation. For this purpose,
lung mechanics and histology, elastic and collagen ﬁber content in
airways and alveolar septa, the amount of smooth muscle-speciﬁc
actin present in distal airways and alveolar duct walls, and the
expressionof inﬂammatorycytokinesandgrowth factorswereana-
lyzed.
Open access under the Elsevier OA license.2. Material and methods
This study was approved by the Ethics Committee of the Health
Sciences Centre, Federal University of Rio de Janeiro. All animals
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eceived humane care in compliance with the “Principles of Labo-
atory Animal Care” formulated by the National Society for Medical
esearch and the “Guide for the Care and Use of Laboratory Ani-
als” prepared by the National Academy of Sciences, USA.
.1. Extraction and characterization of bone marrow-derived
ononuclear cells
Bone marrow cells were extracted from male C57BL/6 (20–25g,
= 13) mice and administered on the day of collection. BMDMC
rom GFP+male mice (20–22g, n=3) were administered to 16
57BL/6 femalemice to evaluate thedegree of pulmonaryGFP+ cell
ngraftment. Brieﬂy, under anesthesia with ketamine (25mg/kg)
nd xylazine (2mg/kg) iv, bone marrow cells were aspirated from
he femur and tibia by ﬂushing the bone marrow cavity with
ulbecco’s modiﬁed Eagle’s medium (DMEM) (Life Technologies,
rand Island, NY, USA). After a homogeneous cell suspension was
chieved, cells were centrifuged (400× g for 10min), re-suspended
n DMEM and added to Ficoll-Hypaque (Histopaque 1083, Sigma
hemical Co., St. Louis,MO,USA), andagain centrifugedand supple-
ented with phosphate-buffered saline (PBS). Cells were counted
n a Neubauer chamber with Trypan Blue for evaluation of via-
ility. For the administration of saline or BMDMC, mice were
nesthetized with sevoﬂurane, the jugular vein of each mouse
as dissected, and cells were slowly injected. A small aliquot of
he mononuclear cells was used for immunophenotipic character-
zation of the injected cell population. Cell characterization was
erformed by ﬂow cytometry using antibodies CD45 (leukocyte),
D34 (hematopoietic precursors), CD3, CD8, and CD4 (T lym-
hocyte), CD14 (monocytes and macrophages), CD11b, CD29 and
D45- (non-hematopoietic precursors), all from BD Biosciences,
SA.
.2. Animal preparation and experimental protocolEighty female C57BL/6mice (20–25g)were used. Lungmechan-
cs and histology as well as molecular biology were analyzed in
4 female C57BL/6 mice (n=6/group). Of the remaining 56 female
57BL/6mice, 20 (n=5/group)wereused to computeairwayhyper-
ig. 1. Schematic ﬂow chart (A) and timeline (B) of the study design. C: mice sensitized
AL: mice treated with intravenous injection of saline; CELL: mice treated with BMDMC (Neurobiology 175 (2011) 153–163
responsiveness, 20 to evaluate total and differential cell count in
bronchoalveolar lavage ﬂuid (BALF, n=5/group) and 16 to evaluate
the degree of pulmonary GFP+ cell engraftment (n=4/group). All
females were randomly assigned to two groups. In the OVA group,
micewere immunizedusinganadjuvant-freeprotocol by intraperi-
toneal injection of sterile ovalbumin (OVA, 10g of OVA in 100l)
on 7 alternate days. Forty days after the beginning of sensitiza-
tion, 20g of OVA in 20l saline was intratracheally instilled. This
procedure was performed 3 times with 3-day intervals between
applications (Xisto et al., 2005). The control group (C) received
saline using the same protocol. C and OVA groups were further
randomized to receive saline solution (0.9% NaCl, 50l, SAL) or
BMDMC (2×106 in 50l, CELL) administration through the left
jugular vein 24h before the ﬁrst challenge (Fig. 1).
2.3. Mechanical parameters
Twenty-four hours after the last intratracheal challenge with
saline or OVA, animals were sedated (diazepam 1mg ip),
anesthetized (thiopental sodium 20mg/kg ip), tracheotomized,
paralyzed (vecuronium bromide, 0.005mgkg iv), and ventilated
with a constant ﬂow ventilator (Samay VR15; Universidad de
la Republica, Montevideo, Uruguay) with the following parame-
ters: frequency of 100 breaths/min, tidal volume (VT) of 0.2ml,
and fraction of inspired oxygen of 0.21. The anterior chest wall
was surgically removed and a positive end-expiratory pressure of
2 cmH2O applied. Airﬂow and tracheal pressure (Ptr) were mea-
sured (Burburan et al., 2007). Lung mechanics was analyzed by the
end-inﬂation occlusionmethod (Bates et al., 1988). In anopen chest
preparation, Ptr reﬂects transpulmonary pressure (PL). Brieﬂy, after
end-inspiratory occlusion, there is an initial fast drop in PL (P1)
from the preocclusion value down to an inﬂection point (Pi), fol-
lowed by a slow pressure decay (P2), until a plateau is reached.
This plateau corresponds to the elastic recoil pressure of the lung
(Pel). P1 selectively reﬂects the pressure used to overcome the
airway resistance. P2 reproduces the pressure spent by stress
relaxation, or viscoelastic properties of the lung, together with
a small contribution of pendelluft. Static lung elastance (Est) was
determined by dividing Pel by VT. Lung mechanics measurements
and challenged with saline; OVA: mice sensitized and challenged with ovalbumin;
2×106) 24h before the ﬁrst challenge. All data were analyzed at day 47.
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ere performed 10 times in each animal. All data were analyzed
sing ANADAT data analysis software (RHT-InfoData, Inc., Mon-
real, Quebec, Canada).
.4. Airway responsiveness
Twenty-four hours after the last challenge, airway responsive-
esswasmeasured. One dose of saline (Baseline)was administered
ollowed by increasing doses of methacholine (Sigma Chemical
o., Saint Louis, MI, USA) (3, 10, 30, and 100g/kg) via a sylas-
ic catheter tied into the jugular vein. Data were stored at 30 s,
, 3, and 5min after methacholine injection. Airﬂow and Ptr were
easured after achieving themaximal increase in Ptr that followed
ach intravenous infusion of methacholine (Xisto et al., 2005). Res-
iratory system resistance was obtained using the equation of
otion of respiratory system: Ptr (t) =E·V(t) +R·V′(t), where (t) is
ime. Resistance was expressed as a percentage of baseline mea-
urements.
.5. Lung histology
A laparotomy was done immediately after the determination of
ung mechanics and heparin (1000 IU) was intravenously injected
n the vena cava. The trachea was clamped at end-expiration, and
he abdominal aorta and vena cava were sectioned, yielding a
assive hemorrhage that quickly killed the animals. Right lung
as then removed, ﬁxed in 3% buffered formaldehyde and paraf-
n embedded. Four-m-thick slices were cut and stained with
ematoxylin–eosin.
Lung histology analysis was performed with an integrating eye-
iece with a coherent system consisting of a grid with 100 points
nd 50 lines (known length) coupled to a conventional light micro-
cope (Olympus BX51, Olympus Latin America-Inc., Brazil). Volume
raction of collapsed and normal pulmonary areas, the magnitude
f bronchoconstriction, and the number of mononuclear and poly-
orphonuclear cells in pulmonary tissue were determined by the
oint-counting technique (Weibel, 1990; Hsia et al., 2010) across
0 random, non-coincident microscopic ﬁelds (Xisto et al., 2005;
urburan et al., 2007).
Collagen (Picrosirius-polarization method) and elastic ﬁbers
Weigert’s resorcin fuchsin method with oxidation) were quanti-
ed in airways and alveolar septa (Xisto et al., 2005; Antunes et al.,
009, 2010).
.6. Transmission electron microscopy
Three 2mm×2mm×2mm slices were cut from three differ-
nt segments of the left lung and ﬁxed [2.5% glutaraldehyde and
hosphate buffer 0.1M (pH 7.4)] for electron microscopy (JEOL
010 Transmission Electron Microscope, Tokyo, Japan) analysis.
or each electron microscopy image (20/animal), the following
tructural changes were analyzed: a) epithelial detachment, b) air-
ay edema, c) eosinophil inﬁltration, d) neutrophil inﬁltration, e)
egenerative changes in ciliated airway epithelial cells, f) subep-
thelial ﬁbrosis, g) elastic ﬁber fragmentation, h) smooth muscle
ypertrophy, i)myoﬁbroblast hyperplasia, j)mucous cell hyperpla-
ia, and l)multinucleated cells (Antunes et al., 2010). Thepathologic
ndings were graded according to a 5-point semi-quantitative
everity-based scoring system as: 0 =normal lung parenchyma,
= changes in 1–25%, 2 = changes in 26–50%, 3 = changes in 51–75%,
nd 4= changes in 76–100% of examined tissue..7. Confocal microscopy
Fluorescent images of basement membrane were obtained
sing a confocal microscope (Leica Microsystems Ltd., Heidelberg,Neurobiology 175 (2011) 153–163 155
Germany). Tissue sectionswere pretreatedwith PBS for 30min and
incubated overnight at room temperature in a humidiﬁed chamber
with a mouse antibody against type V collagen (1:50), followed
by double staining with ﬂuorescein and rhodamine (rhodamine-
conjugated goat anti-mouse IgG-R, dilution 1:40, Santa Cruz
Biotechnology, Santa Cruz, CA). For recipients of GFP marrow
transplants, frozen sections were treated with 4′,6-diamidino-
2-phenylindole dihydrochloride (DAPI)-supplemented mounting
medium (Vectashield, Vector Labs, Burlingame, CA), cover slipped
and examined for GFP expression by confocal microscopy. Back-
ground autoﬂuorescence was determined through examination
of 10 simultaneously prepared negative control sections that
were stained only with DAPI. Images were processed and recon-
structed by using NIH Image software and contrast and color
levels were adjusted with Adobe Photoshop 7.0. The number of
GFP+ cells per tissue area was determined by the point-counting
technique (Weibel, 1990; Araújo et al., 2010) across 10 random,
non-coincident microscopic ﬁelds.
2.8. Evaluation of BALF
Lungs were lavaged via a tracheal tube with PBS solution (1ml)
containing EDTA (10mN). Total leukocyte numbersweremeasured
in Neubauer chambers under light microscopy after diluting the
samples in Türk solution (2% acetic acid). Differential cell counts
were performed in cytospin smears stained by the May-Grünwald-
Giemsa method.
2.9. Expression of growth factors and IL-5
Quantitative real-time reverse transcription (RT) polymerase
chain reaction (PCR) was performed to measure the expression
of interleukin (IL)-5, transforming growth factor (TGF)-, platelet
derived growth factor (PDGF), vascular endothelial growth fac-
tor (VEGF) and insulin-like growth factor (IGF) genes. Central
slices of left lungs were cut, collected in cryotubes, quick-frozen
by immersion in liquid nitrogen, and stored at −80 ◦C. Total
RNA was extracted from the frozen tissues, using the Trizol
reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s
recommendations. RNA concentration was measured by spec-
trophotometry in Nanodrop® ND-1000. First-strand cDNA was
synthesized from total RNA using M-MLV Reverse Transcriptase
Kit (Invitrogen, Carlsbad, CA). PCR primers for target gene were
purchased (Invitrogen, Carlsbad, CA). The following primers were
used: IL-5 [5′-AAC TGT CCG TGG GGG TAC T-3′ (forward) and 5′-
CTC GTC CTC CGT CTC TCC T-3′ (reverse)], VEGF [5′-CCA CGA CAG
AAG GAG AGC A-3′ (forward) and 5′-AAT CGG ACG GCA GTA GCT T-
3′ (reverse)], TGF- [5′-ATA CGC CTG AGT GGC TGT C-3′ (forward)
and 5′-GCCCTGTAT TCCGTC TCC T-3′ (reverse)], PDGF [5′-TCGAAG
TCA GAT CCA CAG CA-3′ (forward) and 5′-CTT GTC TCC AAG GCA
TCC TC-3′ (reverse)], IGF [5′-CTGGTGGATGCT CTT CAGTTC-3′ (for-
ward) and 5′-CCAGTC TCC TCAGAT CACAGC-3′ (reverse)]. Relative
mRNA levels were measured with a SYBR green detection system
usingABI7500Real-TimePCR (AppliedBiosystems, FosterCity, CA).
All samples were measured in triplicate. The relative expression
of each gene was calculated as a ratio compared with the refer-
ence gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
[5′-AAC TTT GGC ATT GTG GAA GG-3′ (forward) and 5′-GTC TTC
TGG GTG GCA GTG AT-3′ (reverse)] and expressed as fold change
relative to C-SAL.2.10. Statistical analysis
Normality of data was tested using the Kolmogorov–Smirnov
test with Lilliefors’ correction, while the Levene median test was
used to evaluate the homogeneity of variances. If both condi-
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ions were satisﬁed, two-way ANOVA followed by Tukey’s test
hen requiredwas used to compare differences among the groups.
onparametric data were analyzed using two-way ANOVA on
anks followed by Tukey’s test. Parametric data were expressed
s means± SEM, while non-parametric data were expressed as
edians (interquartile range). All tests were performed using the
igmaStat 3.1 statistical software package (Jandel Corporation, San
aphael, CA, USA), and statistical signiﬁcance was established as
<0.05.
. Results
The pool of intravenously injected BMDMC was characterized
y ﬂow cytometry showing the following subpopulations: total
ymphocyte (lower SSC, CD45+/CD11b−/ CD29−/ CD34−=29.7%),
lymphocyte (lower SSC/ CD45+/ CD3+/ CD34−=5.4%), T helper
ymphocyte (CD3+/ CD4+/ CD8−=2.4%), T cytotoxic lymphocyte
CD3+/CD4−/ CD8+=2.3%), monocytes (CD45+/ CD29+/ CD11b+
ow/ CD34−/CD3−=4.9%), neutrophils (CD45+/ CD11b+/ CD34−/
D29−/ CD14−/ CD34−/ CD3−), hematopoietic progenitors
CD34+/CD45+=0.3%), and other progenitors cells (CD45−=3.8%)
data presented in Fig. S.1 in the Supplementary Material).
Est (33%),P1 (15%), andP2 (49%)were higher in theOVA-SAL
han in the C-SAL group. BMDMC signiﬁcantly inhibited Est, P1,
ndP2alterations (Fig. 2A, B). Furthermore, the increase in airway
esistance evoked by methacholine was signiﬁcantly augmented
he OVA-SAL group; however, these changes were minimized in
VA animals receiving BMDMC (Fig. 2C).
ig. 2. Lung static elastance (Est) (Panel A); resistive (P1, gray bar), viscoelastic (P2, w
ponsiveness (Panel C). C: mice sensitized and challenged with saline; OVA: mice sensiti
f saline (white bars); CELL: mice treated with BMDMC (2×106) 24h before the ﬁrst chaNeurobiology 175 (2011) 153–163
In the OVA-SAL group, morphometric examination of lungs
demonstrated a signiﬁcant increase in the fraction area of alveo-
lar collapse, the number of mononuclear and polymorphonuclear
cells, collagen ﬁber content in airways and alveolar septa and in
the volume proportion of smooth muscle-speciﬁc actin in terminal
bronchioles and alveolar ducts (Table 1). In Fig. 3, a reduction in the
central airway diameter and inﬂammatory cell inﬁltration can be
observed. BMDMC therapy minimized the fraction area of alveolar
collapse and polymorphonuclear cells, and the volume proportion
of smooth muscle-speciﬁc actin in alveolar ducts, but prevented
changes in airway contraction, amount of collagen ﬁber in airway
and alveolar septa, and in volume proportion of smooth muscle
speciﬁc actin in terminal bronchiole. Elastic ﬁber content in airway
and alveolar septa was similar in all groups (Table 1). Additionally,
central airway diameter was observed to be less constricted and
presented a reduction in inﬂammation in OVA-CELL group (Fig. 3).
Fig. 4 depicts typical electronmicroscopy ﬁndings of airway and
lung parenchyma in each group. OVA-SAL animals showed airway
epithelial cell detachment from the basement membrane, degen-
erative changes in ciliated airway epithelial cells, eosinophil and
neutrophil inﬁltration, myoﬁbroblast and mucous cell hyperplasia,
subepithelial ﬁbrosis, and smooth muscle hypertrophy (Table 2).
BMDMC therapy attenuated all these ultrastructural changes and
promoted the appearance of undifferentiated cells, without a
deﬁned phenotype, and multinucleated cells (Table 2).
Confocal microscopy showed basement membrane rupture
associated with increased inﬂammatory process in the OVA-SAL
group, which was prevented with the use of BMDMC (Fig. 5).
hite bar) and total pressures (Ptot =P1+P2) (Panel B); and airway hyperre-
zed and challenged with ovalbumin; SAL: mice treated with intravenous injection
llenge. *Signiﬁcantly different from C-SAL (p<0.05).
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Table 1
Lung morphometry.
C-SAL C-CELL OVA-SAL OVA-CELL
Normal (%) 99.0 ± 0.72 98.0 ± 2.60 68.2 ± 11.1* 88.1 ± 5.91 *#
Collapse (%) 1.00 ± 0.72 1.80 ± 2.69 31.8 ± 11.1* 11.8 ± 5.91*#
MN (%) 33.13 ± 2.90 29.35 ± 3.20 51.2 ± 3.06* 29.03 ± 1.61
PMN (%) 0.30 ± 0.32 3.00 ± 1.06* 7.20 ± 0.96* 3.64 ± 1.63*#
Contraction index 2.28 ± 0.32 2.25 ± 0.32 3.02 ± 0.51* 2.39 ± 0.31
Collagen ﬁber (m2/m) Airways 1.04 ± 0.05 1.02 ± 0.05 3.30 ± 0.40* 1.06 ± 0.15
Alveolar septa 0.014 ± 0.03 0.014 ± 0.03 0.070 ± 0.007* 0.011 ± 0.002
Elastic ﬁber (m2/m) Airways 1.47 ± 0.17 1.35 ± 0.28 1.40 ± 0.15 1.39 ± 0.20
Alveolar septa 0.26 ± 0.04 0.25 ± 0.05 0.27 ± 0.02 0.26 ± 0.01
Actin (%) Terminal bronchiole 3.11 ± 0.36 2.98 ± 0.36 6.70 ± 0.80* 4.08 ± 0.42
Alveolar duct 0.23 ± 0.17 1.05 ± 0.19 2.08 ± 0.17* 1.87 ± 0.21*#
The fraction of area of normal and collapsed alveoli, mononuclear (MN) and polymorphonuclear (PMN) cells, contraction index, collagen and elastic ﬁbers in airways and
alveolar septa, volume proportion of smooth muscle-speciﬁc actin in terminal bronchiole and alveolar duct. All values were computed in ten random, non-coincident ﬁelds
per mice. C: mice sensitized and challenged with saline; OVA: mice sensitized and challenged with ovalbumin; SAL: mice treated with intravenous injection of saline; CELL:
mice treated with BMDMC (2×106) 24h before the ﬁrst challenge. *Signiﬁcantly different from C-SAL (p<0.05). #Signiﬁcantly different from OVA-SAL (p<0.05).
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dig. 3. Representative photomicrographs of airways stained with hematoxylin–eosin. N
black arrows) in theOVA-SAL group. C:Mice sensitized and challengedwith saline; OVA:m
njection of saline; CELL: mice treated with BMDMC (2×106) 24h before the ﬁrst challen
able 2
emi-quantitative analysis of electron microscopy.
C-SAL
Epithelial detachment 0 (0–0)
Airway edema 0 (0–0)
Eosinophil inﬁltration 0 (0–0)
Neutrophil inﬁltration 0 (0–0)
Degeneration of ciliated airway epithelial cells 0 (0–0)
Subepithelial ﬁbrosis 0 (0–0)
Elastic ﬁber fragmentation 0 (0–0)
Smooth muscle hypertrophy 0 (0–0)
Myoﬁbroblast hyperplasia 0 (0–0)
Mucous cells hyperplasia 0 (0–0)
Multinucleated cells 0 (0–0)
athologic ﬁndings were graded according to a 5-point semi-quantitative severity-base
=51–75%, and 4=76–100% of the examined tissue. C: mice sensitized and challenged wi
ith intravenous injection of saline; CELL: mice treated with BMDMC (2×106) 24h bef
ifferent from C-CELL (p<0.05). #Signiﬁcantly different from OVA-SAL (p<0.05).ote the reduction in central airway diameter as well as increased cell inﬁltration
ice sensitized and challengedwith ovalbumin; SAL:mice treatedwith intravenous
ge. Original magniﬁcation: ×400. Bars =100m.
C-CELL OVA-SAL OVA-CELL
0 (0–0) 2 (2–3)* 1 (0–1)*#
0 (0–0) 3 (2–4)* 1 (0–2)*#
0 (0–0) 3 (2–4)* 1 (1–2)*#
1 (0–1)* 2 (1–3)* 1 (0–2)*#
0 (0–0) 3 (3–4)* 1 (1–2)*#
0 (0–0) 3 (3–4)* 1 (1–2)*#
0 (0–0) 2 (2–3)* 0 (0–1)
0 (0–0) 3 (2–4)* 1 (1–2)*#
0 (0–0) 3 (3–4)* 1 (1–2)*#
0 (0–0) 3 (2–4)* 1 (0–2)*#
1 (0–1)* 0 (0–0) 2 (1–3)*§
d scoring system: 0=normal lung parenchyma, 1 = changes in 1–25%, 2 =26–50%,
th saline; OVA: mice sensitized and challenged with ovalbumin; SAL: mice treated
ore the ﬁrst challenge. *Signiﬁcantly different from C-SAL (p<0.05). §Signiﬁcantly
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F ma (r
a clear
c erent
p neutro
C
c
B
Cig. 4. Electron microscopy of terminal bronchiole (left panels) and lung parenchy
nd challenged with ovalbumin; SAL: saline; CELL: bone marrow-derived mononu
ells [Muc(m)] ciliated cells (Cil), alveolar ducts (AD), alveolar lumen (Alv), undiff
neumocytes type II (PII*), capillary (Cap), apoptosis (arrows), MF (myoﬁbroblast),A very small number of GFP+ cells was detected in the OVA-
ELL group (<1%), vs. none in C-CELL (Fig. 6). The number of total
ells and eosinophils in BALF was higher in OVA-SAL (Fig. 7A, B).
MDMC yielded an increase in the number of total cells in the C-
ELL group resulting froman increasedmonocyte count (Fig. 7A, C).ight panels). C: mice sensitized and challenged with saline; OVA: mice sensitized
cell therapy. Basal membrane (BM), mucous cells (Muc), multinucleated mucous
iated cells (Cund), alveolar septa (Sep), pneumocytes type II (PII), multinucleated
phils (N).In the OVA-CELL group, the number of total cells and eosinophils
was lower than in OVA-SAL.
IL-5, TGF-, PDGF, VEGF, and IGF mRNA expressions in lung tis-
sue were higher in OVA-SAL (Fig. 8A–E). BMDMC administration
promoted an increase in IGF mRNA expression in the C-CELL and
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Fig. 5. Representative photomicrographs of airways and lung parenchyma using confocal microscopy. Note, in green, rupture of basement membrane (arrows) in the OVA-
SAL group. Basement membrane (BM), epithelial cells (Epi), terminal bronchiole (Br), alveolar duct (AD), vessel (Ves), and type II pneumocyte (PII). C: Mice sensitized and
challenged with saline; OVA: mice sensitized and challenged with ovalbumin; SAL: mice treated with intravenous injection of saline; CELL: mice treated with BMDMC
(2×106) 24h before the ﬁrst challenge. Original magniﬁcation: ×400. Bars =100m. (For interpretation of the references to color in this ﬁgure legend, the reader is referred
to the web version of the article.)
Fig. 6. Confocal microscopy of lung parenchyma in C and OVA C57BL/6 female mice treated from BMDMC from GFP male mice. C: mice sensitized and challenged with
saline; OVA: mice sensitized and challenged with ovalbumin; CELL: mice treated with BMDMC (2×106) 24h before the ﬁrst challenge. Note that few GFP+ cells (green) were
present in the lung parenchyma. Original magniﬁcation: ×200. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of
the article.)
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ith saline; OVA: mice sensitized and challenged with ovalbumin; SAL: mice trea
efore the ﬁrst challenge. *Signiﬁcantly different from C-SAL (p<0.05). #Signiﬁcant
VA-CELL groups (Fig. 8E), as well as a reduction in IL-5, TGF-,
DGF, and VEGF expressions in OVA-CELL (Fig. 8A–D).
. Discussion
In the present murine model of chronic allergic inﬂammation,
arly intravenous BMDMC therapy led to: 1) a signiﬁcant reduc-
ion in lung static elastance, resistive and viscoelastic pressures,
irway hyperresponsiveness, fraction area of alveolar collapse,
ronchoconstriction index, number of cells in lung tissue and
ALF, collagen ﬁber content, and volume proportion of smooth
uscle-speciﬁc actin; and 2) repair of airway epithelium, reduc-
ng detachment of basement membrane, subepithelial ﬁbrosis and
yoﬁbroblast hypertrophy and hyperplasia. These results were
chieved despite a small degree of pulmonary engraftment, sug-
esting a prominent role of paracrine effects.
We developed a model of chronic allergic inﬂammation in
57BL/6 mice. Although this model has been described in BALB/c
ice (Xisto et al., 2005; Burburan et al., 2007; Antunes et al., 2009,
010), C57BL/6 mice were used since they serve as a background
train for GFP mice. Indeed, C57BL/6 remodeled differently from
ALB/c mice considering the same experimental chronic allergic
nﬂammation model (Antunes et al., 2009); however, the ultra-
tructural changes of airway and lung parenchyma, although less
ntense, were similar to those observed in BALB/c mice.
Previous experimental studies have investigated the restorative
apacity of bonemarrowmesenchymal stem cells (MSC) in respira-nocytes (Panel D) in bronchoalveolar lavage ﬂuid. C:mice sensitized and challenged
th intravenous injection of saline; CELL: mice treated with BMDMC (2×106) 24h
erent from OVA-SAL (p<0.05).
tory diseases (Rojas et al., 2005;Gupta et al., 2007;Ortiz et al., 2007;
Zhao et al., 2008; Zhen et al., 2008). However, MSC present dis-
advantages, such as culture conditions, which are detrimental for
cell transplantation, and risk of contamination and immunologic
reactions. Based on these limitations, we chose BMDMC, which
we can be easily and safely administered on the day of harvest-
ing, express several genes involved in inﬂammatory response and
chemotaxis (Ohnishi et al., 2007), and present lower cost compared
to MSC. Therefore, BMDMC therapy is applicable in clinical set-
tings. To our knowledge, this is the ﬁrst study investigating the
effectsofBMDMCtherapyon lung functionand the remodelingpro-
cess in experimental chronic allergic inﬂammation. BMDMC were
administered 24h before the ﬁrst ovalbumin challenge protocol,
since the inﬂammatory process, characterized in the presentmodel
by an increase in eosinophils in lung tissue, is essential for cell
recruitment to the injured area (Herzog et al., 2006). The possi-
bility of antigen mismatch was considered taking into account the
administration of male BMDMC in females. However, pilot studies
demonstrated that similar results were obtained independently of
the sex of BMDMC donors. GFP-positive cells were used to iden-
tify homing of bone marrow cells in lung parenchyma. A very small
number was observed in the OVA-CELL group, but not in C-CELL
lungs, suggesting that tissue injury is necessary to attract and retain
these cells.
Several studies have shown that the airway epithelium of asth-
matic patients has lower regenerative ability since these patients
have a small number of circulating progenitor cells (Holgate, 2008).
Therefore, the administration of BMDMC may potentiate airway
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Fig. 8. Real-time polymerase chain reaction analysis of IL-5: interleukin-5 (Panel A), VEGF: vascular endothelial growth factor (Panel B), TGF-: transforming growth factor-
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eeta (Panel C), PDGF: platelet derived growth factor (Panel D), and IGF: insulin g
hallenged with saline; OVA: mice sensitized and challenged with ovalbumin; SA
2×106) 24h before the ﬁrst challenge. *Signiﬁcantly different from C-SAL (p<0.05
pithelial cell repair as well as reduce remodeling and inﬂamma-
ory processes through paracrine effects. Ultrastructural analysis
sing electron and confocal microscopy showed repair of ciliated
irway epithelial cells associated with a reduction in subepithelial
brosis and smooth muscle cell hypertrophy and hyperplasia. We
lso observed the presence of many multinucleated and undiffer-
ntiated cells in lung parenchyma, suggesting that these cells can
e an important source for the repair of damaged area. These mult-
nucleated cells could be macrophages that fused with BMDMC or
ith injuredepithelial cells (Krause, 2008). Additionally, it has been
escribed that macrophages behave in vitro as stem cell attractors.
nce at the site of injury, the ability of precursor cells to reconsti-
ute the damaged tissue depends on the signals generated in situ
y themacrophages (Lolmede et al., 2009). However, in accordance
ithprevious reports inother lungdiseases, thebeneﬁcial effects of
ell therapy in the present study seem to have been mainly related
o paracrine effects modulating immune responses through the
elease of cytokines and growth factors (Krause et al., 2001; Ortiz
t al., 2003; Abe et al., 2004; Yamada et al., 2004; Araújo et al.,factor (Panel E) mRNA expressions of mouse lung tissue. C: mice sensitized and
ce treated with intravenous injection of saline; CELL: mice treated with BMDMC
niﬁcantly different from OVA-SAL (p<0.05).
2010). Even though BMDMC therapy led to an increased number
of total cells in the BALF of controls, which may be attributed to
the percentage of donor hematopoietic cells in BMDMC (Ratajczak
et al., 2004), it signiﬁcantly reduced the number of total cells and
eosinophils in OVA-CELL. We found that BMDMC therapy caused a
reduction in the expression of IL-5, which plays an important role
in the remodeling process of asthma. Therefore, this reduction can
be associated with the decrease in the number of eosinophils in the
BALF and in TGF- expression. Consequently, therewas a reduction
in myoﬁbroblast activation (Tanaka et al., 2004), diminishing colla-
genﬁber content andvolumeproportionof smoothmuscle-speciﬁc
actin. Additionally, the decrease in PDGF and VEGF expressions
after cell therapy contributed to a reduction in subepithelial ﬁbro-
sis and smooth muscle layer thickening, as these growth factors
are involved in ﬁbroblast, muscle, and endothelial cell activation
and proliferation (Klagsbrun and D’Amore, 1991; Saunders et al.,
2009). In this line, a recent study has reported that VEGF recep-
tor inhibition led to a signiﬁcant reduction in the inﬂammatory
and remodeling processes in experimental asthma. Conversely,
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MDMC yielded an increase in IGF expression, which may be asso-
iated with the effect of these cells on the re-epithelization process
Yamashita et al., 2005) previously observed in experimental mod-
ls of idiopathic ﬁbrosis. Thus, the paracrine effects of BMDMC
cted on airway and lung parenchyma remodeling resulting in an
mprovement in lung mechanics and reducing airway responsive-
ess.
Our study has some limitations: 1) BMDMC were injected 24h
efore theﬁrst ovalbumin challenge, before the remodelingprocess
as established. Thus,more studies shouldbeperformed toanalyze
MDMC effects after the last challenge; 2) despite the widespread
peculation that MSC constitute a unique cell type distinct from
broblasts (Horwitz et al., 2007), some investigators have used
broblast therapy as control (Mei et al., 2007; Xu et al., 2007).
ince the use of ﬁbroblasts did not result in beneﬁcial effects (Sun
t al., 2009), in the present study we administrated saline as con-
rol instead of ﬁbroblasts; 3) we cannot ascertain whether the role
f cytokines and growth factors is related to engraftment. To clar-
fy this issue, speciﬁc gene deﬁcient animals should be used; and 4)
ven though theamountofGFPwasquantiﬁed in lung tissue,wedid
ot analyze whether these engrafted cells are transdifferentiated
nto any type of lung cell.
In conclusion, in the present murine model of chronic allergic
nﬂammation,bonemarrow-derivedmononuclear cell therapywas
n effective pre-treatment protocol, potentiating airway epithelial
ell repair and reducing inﬂammatory and remodeling processes.
hese results were achieved despite a small degree of pulmonary
ngraftment, suggesting a role of paracrine effects. Additional
xperiments are necessary to analyze the effects of BMDMC after
he remodeling process has been established.
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